Muscarinic receptor occupancy and cognitive impairment: A PET study with 11 C()3-MPB and scopolamine in conscious monkeys

Neuropsychopharmacology

Volumn 36, Issue 7, 2011, Pages 1455-1465

  Yamamoto, Shigeyuki ^a   Nishiyama, Shingo ^b   Kawamata, Masahiro ^b   Ohba, Hiroyuki ^b   Wakuda, Tomoyasu ^a   Takei, Nori ^a   Tsukada, Hideo ^b   Domino, Edward F ^c  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HAMAMATSU PHOTONICS K K   (Japan)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

cognition; monkey; muscarinic receptor; PET; scopolamine

Indexed keywords

CARBON 11; MEPENZOLATE; MUSCARINIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN CORTEX; BRAIN STEM; COGNITION; COGNITIVE DEFECT; DRUG DOSE TITRATION; DRUG EFFECT; FOREBRAIN; MACACA MULATTA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THALAMUS;

ANIMALS; BRAIN; BRAIN MAPPING; CARBON ISOTOPES; COGNITION DISORDERS; CONSCIOUSNESS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LYSINE; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MALEIMIDES; MUSCARINIC ANTAGONISTS; NEUROPSYCHOLOGICAL TESTS; PHOTIC STIMULATION; POSITRON-EMISSION TOMOGRAPHY; REACTION TIME; RECEPTORS, MUSCARINIC; SCOPOLAMINE; TIME FACTORS;

EID: 79956052419     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.31     Document Type: Article

References (99)

1. Ahlskog JE, Richelson E, Nelson A, Kelly PJ, Okazaki H, Tyce GM et al (1991). Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann Neurol 30: 185-191.
2. Aigner TG, Mishkin M (1986). The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 45: 81-87. (Pubitemid 16162297)
3. Alexander GE, Crutcher MD (1990). Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13: 266-271. (Pubitemid 20193456)
4. Baghdoyan HA, Lydic R, Fleegal MA (1998). M2 muscarinic autoreceptors modulate acetylcholine release in the medial pontine reticular formation. J Pharmacol Exp Ther 286: 1446-1452. (Pubitemid 29135561)
5. Bainbridge NK, Koselke LR, Jeon J, Bailey KR, Wess J, Crawley JN et al (2008). Learning and memory impairments in a congenic C57BL/6 strain of mice that lacks the M2 muscarinic acetylcho-line receptor subtype. Behav Brain Res 190: 50-58.
6. Bartus RT, Johnson HR (1976). Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol Biochem Behav 5: 39-46.
7. Bechara A, van der Kooy D (1989). The tegmental pedunculo-pontine nucleus: a brain-stem output of the limbic system critical for the conditioned place preferences produced by morphine and amphetamine. J Neurosci 9: 3400-3409. (Pubitemid 19260014)
8. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A et al (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54: 465-473. (Pubitemid 27172867)
9. Broersen LM, Heinsbroek RP, de Bruin JP, Joosten RN, van Hest A, Olivier B (1994). Effects of local application of dopaminergic drugs into the dorsal part of the medial prefrontal cortex of rats in a delayed matching to position task: comparison with local cholinergic blockade. Brain Res 645: 113-122. (Pubitemid 24140117)
10. Broks P, Preston GC, Traub M, Poppleton P, Ward C, Stahl SM (1988). Modelling dementia: effects of scopolamine on memory and attention. Neuropsychologia 26: 685-700.
11. Buccafusco JJ, Jackson WJ, Gattu M, Terry Jr AV (1995). Isoarecolone-induced enhancement of delayed matching to sample performance in monkeys: role of nicotinic receptors. Neuroreport 6: 1223-1227.
12. Buccafusco JJ, Terry Jr AV, Goren T, Blaugrun E (2003). Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task. Neuroscience 119: 669-678. (Pubitemid 36694795)
13. Buccafusco JJ, Terry Jr AV, Murdoch PB (2002). A computer-assisted cognitive test battery for aged monkeys. J Mol Neurosci 19: 179-185. (Pubitemid 35013353)
14. Caccamo A, Fisher A, LaFerla FM (2009). M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 6:112-117.
15. Chafee MV, Goldman-Rakic PS (1998). Matching patterns of activity in primate prefrontal area 8a and parietal area 7ip neurons during a spatial working memory task. J Neurophysiol 79: 2919-2940. (Pubitemid 28317024)
16. Collerton D (1986). Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19: 1-28. (Pubitemid 16053626)
17. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48: 381-388.
18. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002). Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7: 1083-1091. (Pubitemid 36044267)
19. Dellu F, Mayo W, Cherkaoui J, Le Moal M, Simon H (1991). Learning disturbances following excitotoxic lesion of cholinergic pedunculo-pontine nucleus in the rat. Brain Res 544: 126-132.
20. Drachman DA (1977). Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27: 783-790. (Pubitemid 8171670)
21. Edginton T, Rusted JM (2003). Separate and combined effects of scopolamine and nicotine on retrieval-induced forgetting. Psychopharmacology 170: 351-357. (Pubitemid 38010506)
22. Enna SJ, Bird ED, Bennett Jr JP, Bylund DB, Yamamura HI, Iversen LL et al (1976). Huntington's chorea. Changes in neurotrans-mitter receptors in the brain. N Engl J Med 294: 1305-1309.
23. Everitt BJ, Robbins TW (1997). Central cholinergic systems and cognition. Annu Rev Psychol 48: 649-684. (Pubitemid 127485189)
24. Floresco SB, Braaksma DN, Phillips AG (1999). Thalamic-cortical- striatal circuitry subserves working memory during delayed responding on a radial arm maze. J Neurosci 19: 11061-11071. (Pubitemid 30235749)
25. Flynn DD, Ferrari-DiLeo G, Mash DC, Levey AI (1995). Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 64: 1888-1891.
26. Funahashi S, Bruce CJ, Goldman-Rakic PS (1989). Mnemonic coding of visual space in the monkey's dorsolateral prefrontal cortex. J Neurophysiol 61: 331-349. (Pubitemid 19063448)
27. Green A, Ellis KA, Ellis J, Bartholomeusz CF, Ilic S, Croft RJ et al (2005). Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans. Pharmacol Biochem Behav 81: 575-584. (Pubitemid 40966805)
28. Hampson RE, España RA, Rogers GA, Porrino LJ, Deadwyler SA (2009). Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717. Psychopharmacology 202: 355-369.
29. Hannula DE, Tranel D, Cohen NJ (2006). The long and the short of it: relational memory impairments in amnesia, even at short lags. J Neurosci 26: 8352-8359. (Pubitemid 44309849)
30. Haraguchi K, Ito K, Kotaki H, Sawada Y, Iga T (1997). Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies. Drug Metab Dispos 25: 675-684. (Pubitemid 27259966)
31. Hardman JG, Limbird LE (1996). Goodman and Gilman's the Pharmacological Basis of Therapeutics. McGraw-Hill: New York. . pp 149-150.
32. Hasselmo ME, Stern CE (2006). Mechanisms underlying working memory for novel information. Trends Cogn Sci 10: 487-493. (Pubitemid 44602572)
33. Herremans AH, Hijzen TH, Welborn PF, Olivier B, Slangen JL (1996). Effects of infusion of cholinergic drugs into the prefrontal cortex area on delayed matching to position performance in the rat. Brain Res 711: 102-111. (Pubitemid 26081842)
34. Hohmann C, Antuono P, Coyle JT (1998). Basal forebrain cholinergic neurons and Alzheimer's disease. In: Iversen LL, Iversen SD, Snyder SD (eds). Psychopharmacology of the Aging Nervous System. Plenum Press: New York. . P 69-106.
35. Honer WG, Prohovnik I, Smith G, Lucas LR (1988). Scopolamine reduces frontal cortex perfusion. J Cereb Blood Flow Metab 8: 635-641.
36. Hudzik TJ, Wenger GR (1993). Effects of drugs of abuse and cholinergic agents on delayed matching-to-sample responding in the squirrel monkey. J Pharmacol Exp Ther 265: 120-127. (Pubitemid 23320951)
37. Inglis WL, Olmstead MC, Robbins TW (2001). Selective deficits in attentional performance on the 5-choice serial reaction time task following pedunculopontine tegmental nucleus lesions. Behav Brain Res 123: 117-131. (Pubitemid 32496511)
38. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN et al (2007). Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539. (Pubitemid 47301451)
39. Kitabatake Y, Hikida T, Watanabe D, Pastan I, Nakanishi S (2003). Impairment of reward-related learning by cholinergic cell ablation in the striatum. Proc Natl Acad Sci USA 100: 7965-7970. (Pubitemid 36760078)
40. Kobayashi Y, Inoue Y, Yamamoto M, Isa T, Aizawa H (2002). Contribution of pedunculopontine tegmental nucleus neurons to performance of visually guided saccade tasks in monkeys. J Neurophysiol 88: 715-731. (Pubitemid 34874405)
41. Kozak R, Bowman EM, Latimer MP, Rostron CL, Winn P (2005). Excitotoxic lesions of the pedunculopontine tegmental nucleus in rats impair performance on a test of sustained attention. Exp Brain Res 162: 257-264. (Pubitemid 40543837)
42. Kubo T, Fukuda K, Mikami A, Maeda A, Takahashi H, Mishina M et al (1986). Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 323: 411-416. (Pubitemid 16026268)
43. Lange KW, Javoy-Agid F, Agid Y, Jenner P, Marsden CD (1992). Brain muscarinic cholinergic receptors in Huntington's disease. J Neurol 239: 103-104.
44. Langmead CJ, Watson J, Reavill C (2008). Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117: 232-243.
45. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991). Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11: 3218-3226.
46. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996). Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840. (Pubitemid 26292051)
47. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747. (Pubitemid 20260955)
48. Matsumura M, Watanabe K, Ohye C (1997). Single-unit activity in the primate nucleus tegmenti pedunculopontinus related to voluntary arm movement. Neurosci Res 28: 155-165. (Pubitemid 27267825)
49. Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1983). Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214: 170-197. (Pubitemid 13162962)
50. Mesulam MM, Mufson EJ, Levey AI, Wainer BH (1984). Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry. Neuroscience 12: 669-686. (Pubitemid 14092485)
51. Mesulam MM, Mufson EJ, Wainer BH (1986). Three-dimensional representation and cortical projection topography of the nucleus basalis (Ch4) in the macaque: concurrent demonstration of choline acetyltransferase and retrograde transport with a stabilized tetramethylbenzidine method for horseradish perox-idase. Brain Res 367: 301-308. (Pubitemid 16011692)
52. Mewaldt SP, Ghoneim MM (1979). The effects and interactions of scopolamine, physostigmine and methamphetamine on human memory. Pharmacol Biochem Behav 10: 205-210. (Pubitemid 9174488)
53. Miller RJ, Hiley CR (1974). Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature 248: 596-597.
54. Mitchell AS, Dalrymple-Alford JC, Christie MA (2002). Spatial working memory and the brainstem cholinergic innervation to the anterior thalamus. J Neurosci 22: 1922-1928. (Pubitemid 35386311)
55. 11C]methyl-3-piperidyl benzilate in the conscious monkey brain. Synapse 40: 159-169. (Pubitemid 32322208)
56. Ohno M, Yamamoto T, Watanabe S (1992). Effects of intrahippo-campal injections of N-methyl-D-aspartate receptor antagonists and scopolamine on working and reference memory assessed in rats by a three-panel runway task. J Pharmacol Exp Ther 263: 943-950. (Pubitemid 23157164)
57. Owen AM (2000). The role of the lateral frontal cortex in mnemonic processing: the contribution of functional neuroima-ging. Exp Brain Res 133: 33-43. (Pubitemid 30411655)
58. Plakke B, Ng CW, Poremba A (2008). Scopolamine impairs auditory delayed matching-to-sample performance in monkeys. Neurosci Lett 438: 126-130.
59. Penetar DM, McDonough Jr JH (1983). Effects of cholinergic drugs on delayed match-to-sample performance of rhesus monkeys. Pharmacol Biochem Behav 19: 963-967. (Pubitemid 14209520)
60. Perry EK (1986). The cholinergic hypothesisFten years on [review]. Br Med Bull 42: 63-69.
61. Podruchny TA, Connolly C, Bokde A, Herscovitch P, Eckelman WC, Kiesewetter DO et al (2003). In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48: 39-44. (Pubitemid 36249890)
62. Potter DD, Pickles CD, Roberts RC, Rugg MD (2000). Scopolamine impairs memory performance and reduces frontal but not parietal visual P3 amplitude. Biol Psychol 52: 37-52. (Pubitemid 30109235)
63. Prohovnik I, Arnold SE, Smith G, Lucas LR (1997). Physostigmine reversal of scopolamine-induced hypofrontality. J Cereb Blood Flow Metab 17: 220-228. (Pubitemid 27085846)
64. Quirion R, Wilson A, Rowe W, Aubert I, Richard J, Doods H et al (1995). Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. J Neurosci 15: 1455-1462.
65. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al 2003. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 160: 118-127. (Pubitemid 36042435)
66. Rasmusson DD, Dudar JD (1979). Effect of scopolamine on maze learning performance in humans. Experientia 35: 1069-1070. (Pubitemid 9246188)
67. Reinikainen KJ, Riekkinen PJ, Halonen T, Laakso M (1987). Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease. Life Sci 41: 453-461. (Pubitemid 17105224)
68. Rinne JO, Laakso K, Lönnberg P, Mölsä P, Paljärvi L, Rinne JK et al (1985). Brain muscarinic receptors in senile dementia. Brain Res 336: 19-25. (Pubitemid 15013857)
69. Robbins TW, Semple J, Kumar R, Truman MI, Shorter J, Ferraro A et al (1997). Effects of scopolamine on delayed-matching-to-sample and paired associates tests of visual memory and learning in human subjects: comparison with diazepam and implications for dementia. Psychopharmacology 134: 95-106. (Pubitemid 27485554)
70. Rostron CL, Farquhar MJ, Latimer MP, Winn P (2008). The pedunculopontine tegmental nucleus and the nucleus basalis magnocellularis: do both have a role in sustained attention? BMC Neurosci 9: 16.
71. Rowe WB, O'Donnell JP, Pearson D, Rose GM, Meaney MJ, Quirion R (2003). Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats. Behav Brain Res 145: 171-178. (Pubitemid 37188642)
72. Rusted JM, Warburton DM (1988). The effects of scopolamine on working memory in healthy young volunteers. Psychopharma-cology 96: 145-152.
73. Sawaguchi T, Goldman-Rakic PS (1991). D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251: 947-950. (Pubitemid 21926192)
74. Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E, Gomeza J et al (2004). M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 24: 10117-10127. (Pubitemid 39492037)
75. Sellin AK, Shad M, Tamminga C (2008). Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr 13: 985-996.
76. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C et al (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033-1039.
77. Sitaram N, Weingartner H, Gillin JC (1978). Human serial learning: enhancement with arecholine and choline impairment with scopolamine. Science 201: 274-276. (Pubitemid 8396756)
78. Spinelli S, Ballard T, Feldon J, Higgins GA, Pryce CR (2006). Enhancing effects of nicotine and impairing effects of scopola-mine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys. Neuropharmacology 51: 238-250. (Pubitemid 44061881)
79. Steckler T, Keith AB, Sahgal A (1994). Lesions of the pedunculo-pontine tegmental nucleus do not alter delayed non-matching to position accuracy. Behav Brain Res 61: 107-112. (Pubitemid 24097024)
80. 0s rewarding effects but not its memory-improving effect. Behav Neurosci 108: 972-980. (Pubitemid 24322268)
81. Supèr H, Spekreijse H, Lamme VA (2001). A neural correlate of working memory in the monkey primary visual cortex. Science 293: 120-124. (Pubitemid 32625508)
82. Taffe MA, Weed MR, Gold LH (1999). Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery. Brain Res Cogn Brain Res 8: 203-212. (Pubitemid 29518307)
83. Taffe MA, Weed MR, Gutierrez T, Davis SA, Gold LH (2002). Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys. Psycho-pharmacology 160: 253-262. (Pubitemid 34230677)
84. 11C]methyl-3-piperidyl benzilate as a potent radioligand for positron emission tomography. Appl Radiat Isot 50: 521-525. (Pubitemid 29067607)
85. Tang Y, Mishkin M, Aigner TG (1997). Effects of muscarinic blockade in perirhinal cortex during visual recognition. Proc Natl Acad Sci USA 94: 12667-12669. (Pubitemid 27492586)
86. Terry Jr AV, Buccafusco JJ (2003). The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306: 821-827. (Pubitemid 37025286)
87. 2 receptor availability in vivo by regulating receptor affinity induced by facilitated synaptic dopamine turnover: positron emission tomography studies with microdialysis in the conscious monkey brain. J Neurosci 20: 7067-7073.
88. 1) receptors: PET studies in the conscious monkey brain. Synapse 42: 258-265. (Pubitemid 33027299)
89. 11)C]methyl-3-piperidyl benzilate in the brains of conscious monkeys. Synapse 41: 248-257. (Pubitemid 32691508)
90. Tsukada H, Nishiyama S, Fukumoto D, Ohba H, Sato K, Kakiuchi T (2004). Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse 52: 1-10. (Pubitemid 38316265)
91. 11C]4-MPB. Synapse 39: 182-192. (Pubitemid 32104024)
92. Turchi J, Saunders RC, Mishkin M (2005). Effects of cholinergic deafferentation of the rhinal cortex on visual recognition memory in monkeys. Proc Natl Acad Sci USA 102: 2158-2161. (Pubitemid 40262028)
93. Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J et al (2003). Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/ M4 muscarinic receptor knockout mice. Mol Psychiatry 8: 673-679. (Pubitemid 36980624)
94. Vannucchi MG, Scali C, Kopf SR, Pepeu G, Casamenti F (1997). Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience 79: 837-846. (Pubitemid 27292679)
95. Warren NM, Piggott MA, Perry EK, Burn DJ (2005). Cholinergic systems in progressive supranuclear palsy. Brain 128: 239-249. (Pubitemid 40222593)
96. Wastek GJ, Yamamura HI (1978). Biochemical characterization of the muscarinic cholinergic receptor in human brain: alterations in Huntington's disease. Mol Pharmacol 14: 768-780. (Pubitemid 9026479)
97. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T et al (1997). A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 44: 1277-1282. (Pubitemid 127827087)
98. 11C](+)3-MPB for the muscarinic cholinergic receptor in the living brain of conscious monkey. Synapse (in press).
99. Zavitsanou K, Katsifis A, Mattner F, Huang XF (2004). Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacogy 29: 619-625.